Renal Failure Clinical Trial
Official title:
Evaluating Patient Safety And Ease Of Use Of A Novel Connection-Assist Device For Peritoneal Dialysis
It is estimated that there are currently over 3 million patients receiving dialysis treatment worldwide. With effective pre-dialysis counselling, a majority of patients choose the home-based therapy peritoneal dialysis (PD) but only approximately 11% of prevalent dialysis patients use this modality. Connection-assist devices can overcome the challenges posed by decreased manual dexterity and/or visual acuity, and can allow more patients to be treated with home-based therapies. As part of the CE marking authorization, a connection device has been evaluated for safety and ease of use in a usability study.
The growth in the renal replacement therapy population is primaryly in the elderly age group,
a population with a high frailty and comorbidity burden. Facilitating PD in this group of
patients requires improved PD technology with greater accessibility tailored to patient
needs. Following evaluation of specific barriers to the use of PD including feedback from
established PD patients, a novel connection-assist device has been developed.
As part of the CE marking authorization, the connection device has been evaluated for safety
and ease of use in a study at University Hospitals Birmingham NHS Foundation Trust involving
24 patients and carers.
The evaluated device is designed to assist peritoneal dialysis patients performing their
daily dialysis treatment either for APD or for CAPD. The device facilitates the connection
and disconnection of the dialysis line to the PD catheter transfer set. The connections are
performed inside the device in a protected area, and the patient does not need to touch the
transfer set or the dialysis line while they are unprotected. In addition, the breaking of
the dialysis line frangible and the clamping of the dialysis line are replaced by pushing a
button.
The operating procedure of the device consists of multiple tasks including preparing and
loading the transfer set and dialysis line into the device, performing the handling steps
related to the PD therapy with the device and finally unloading the used material from the
device. Each task comprises several handling steps. During the study, the operating procedure
with the device was simulated and the subjects were connected to a dummy catheter, which was
attached to an apron.
This study recruited established PD patients and carers involved in the delivery of PD.
Carers included healthcare professionals and lay carers.
The study design was divided into three one hour long parts. Firstly, a training session
introduced the operation of the device. Secondly, a break of one hour allowed relaxation and
recovery. Thirdly, a test was carried out to determine whether the subject could use the
device independently with the aid of a quick start guide and the device manual.
The training consisted of two cycles in which the moderator guided the subject and three
cycles in which the subject guided the moderator through the complete handling of the device.
After the break, the subjects were asked to carry out a complete handling cycle themselves.
Subjects could use the quick start guide and the device manual as help. After the unsupported
handling cycle, subjects were asked to complete the NASA Task Load Index (N-TLX)
questionnaire. In the meantime, the moderator left the room to obtain information on observed
use errors. In a final semi-structured interview, the subjects were asked about the reasons
for the observed use errors.
For each subject, one moderator and one observer were involved in the study. The moderator
was the interface between the subject and the device both in training and in testing. This
person was employed by an external agency to avoid any influence on the subject. The observer
saw the handling with the help of a live feed from a separate room. He evaluated the handling
steps in the categories of "safe use" and "use error" according to IEC 62366-1. For each use
error, the observer described the observed situation from his point of view. In addition to
evaluating the effectiveness of the task performance, the subjects were interviewed in a semi
structured way. Here the observations of technique errors were discussed with the subjects in
order to identify the specific causes. In this interview, the subjects were also asked for
their feedback on the general ease of use of the device.
In addition, the subjects were asked about the task load in six different dimensions in the
standardized N-TLX. Task load is a hypothetical construct that represents the cost incurred
by a human operator to achieve a particular level of performance. The dimensions of the N-TLX
are mental, physical and temporal demands as well as performance, effort and frustration in
the task. Each dimension is evaluated on a 20-point scale. This scale is then transferred to
the task load index, which is a scale between 0 and 100 points. To classify the results of
the N-TLX, Eitrheim and Fernandes (2016) state "Workload levels below 50 were perceived as
acceptable."
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02763410 -
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
|
||
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Suspended |
NCT04589065 -
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
|
N/A | |
Completed |
NCT03806998 -
Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
|
Phase 3 | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
Completed |
NCT02116270 -
Accelerated Immunosenescence and Chronic Kidney Disease
|
N/A | |
Completed |
NCT01388270 -
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
|
Phase 4 | |
Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
Completed |
NCT01187953 -
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacroâ„¢ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
|
Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT01008631 -
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers
|
N/A | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Recruiting |
NCT00470769 -
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR
|
N/A | |
Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 |